Leveraging Prior Knowledge in Genome-Edited Gene Therapy: A Game Changer for Development Efficiency

Operation Trialblazer: A Shift Toward Collaborative, Patient-Centered Clinical Development

BALANCING AI ADVANCEMENT Vs DEVELOPMENT

From fragmented reporting to real-time foresight: What the FDA’s AEMS means for pharmacovigilance

What the first Joint Clinical Assessment (JCA) report tells us about the next era of integrated evidence planning and access strategy

Regulatory News: When are single pivotal trials enough for approval? FDA’s latest position and what it means for sponsors

Regulatory Strategy Leadership​

Albarah Al Afandi, MPharm

Albarah is a registered Pharmacist and Trainee Qualified Person.

Catherine Laing

Catherine Laing is a Senior Scientific Director at Fortrea with over 20 years of experience in Clinical Pharmacology.

Dr Ben Monaghan

Dr Monaghan graduated from the University of Nottingham in 2015 (BMBS) and from the School of Pharmacy, University of London, in 2009 (MPharm).